Synergistic anit-cancer compounds
The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.
1 . A method for treating cancer in a human patient in need of such treatment, said method comprising administering to the patient a therapeutically effective amount of a composition comprising an antineoplastic thiol-binding mitochondrial oxidant and an antineoplastic nucleic acid binding agent, said amount providing a synergistic therapeutic cytotoxic effect.
2 . The method of claim 1 , wherein said antineoplastic thiol-binding mitochondrial oxidant comprises an aziridine ring.
3 . The method of claim 1 , wherein said antineoplastic thiol-binding mitochondrial oxidant is a substituted or unsubstituted aziridine-1-carboxamide.
4 . The method of claim 1 , wherein said antineoplastic thiol-binding mitochondrial oxidant has the formula:
wherein
R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein R 4 and R 5 are optionally joined together to form a substituted or unsubstituted 5 to 7 membered ring.
5 . The method of claim 1 , wherein said antineoplastic thiol-binding mitochondrial oxidant is imexon.
6 . The method of claim 4 , wherein R 4 is cyano.
7 . The method of claim 1 , wherein said antineoplastic nucleic acid binding agent is an antineoplastic DNA binding agent.
8 . The method of claim 1 , wherein said antineoplastic nucleic acid binding agent is selected from the group consisting of nitrogen mustard, mitomycin derivative, alkyl sulfonate, nitroso urea, platinum complex, altretamine, and imidazole carboxamide.
9 . The method of claim 1 , wherein said antineoplastic nucleic acid binding agent is selected from the group consisting of nitrogen mustard, imidazole carboxamide, and platinum complex.
10 . The method of claim 1 , wherein said antineoplastic nucleic acid binding agent is selected from the group consisting of melphalan, cyclophosphamide, carmustine, mechlorethamine, thiotepa, chlorambucil, lomustine, ifosfamide, mitomycin C, cisplatin, carboplatin, oxaliplatin and dacarbazine.
11 . The method of claim 1 , wherein said cancer is selected from multiple myeloma, β-lymphocyte plasmacytoma, ovarian cancer, melanoma, leukemia, colon cancer, breast cancer, lung cancers, and pancreatic cancer.
12 . The method of claim 11 , wherein said pancreatic cancer is adenocarcinoma of the pancreas.
13 . The method of claim 5 , wherein said antineoplastic nucleic acid binding agent is not cyclophosphamide.
14 . A method for treating cancer in a patient in need of such treatment, said method comprising administering to the patient a therapeutically effective amount of a composition comprising an antineoplastic thiol-binding mitochondrial oxidant and an antineoplastic antimetabolite base analog, said amount providing a synergistic therapeutic cytotoxic effect.
15 . The method of claim 14 , wherein said antineoplastic thiol-binding mitochondrial oxidant comprises an aziridine ring.
16 . The method of claim 14 , wherein said antineoplastic thiol-binding mitochondrial oxidant has the formula:
wherein
R 1 , R 2 , R 3 , R 4 and R′ are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein R 4 and R 5 are optionally joined to form a substituted or unsubstituted 5 to 7 membered ring.
17 . The method of claim 14 , wherein said antineoplastic thiol-binding mitochondrial oxidant is imexon.
18 . The method of claim 16 , wherein R 4 is cyano.
19 . The method of claim 14 , wherein said antineoplastic antimetabolite base analog is selected from the group consisting of mercaptopurine, thioguanine, azathioprine, fludarabine, cladribine, pentostatin, fluorouracil, cytarabine, capecitabine, gemcitabine, and floxuridine.
20 . The method of claim 14 , wherein said antineoplastic antimetabolite base analog is selected from the group consisting of 5-fluorouracil, cytarabine, and gemcitabine.
21 . The method of claim 14 , wherein said antineoplastic antimetabolite base analog is gemcitabine.
22 . The method of claim 14 , wherein said cancer is selected from multiple myeloma, β-lymphocyte plasmacytoma, ovarian cancer, melanoma, leukemia, colon cancer, breast cancer, lung cancers, and pancreatic cancer.
23 . The method of claim 22 , wherein said pancreatic cancer is adenocarcinoma of the pancreas.
24 . A method for treating cancer in a patient in need of such treatment, said method comprising administering to the patient a therapeutically effective amount of a composition comprising an antineoplastic thiol-binding mitochondrial oxidant and docetaxel, said amount providing a synergistic therapeutic cytotoxic effect.
25 . The method of claim 24 , wherein said antineoplastic thiol-binding mitochondrial oxidant comprises an aziridine ring.
26 . The method of claim 24 , wherein said antineoplastic thiol-binding mitochondrial oxidant has the formula:
wherein
R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein R 4 and R 5 are optionally joined to form a substituted or unsubstituted 5 to 7 membered ring.
27 . The method of claim 26 , wherein R 4 is cyano.
28 . The method of claim 24 , wherein said antineoplastic thiol-binding mitochondrial oxidant is imexon.
29 . The method of claim 24 , wherein said cancer is selected from multiple myeloma, β-lymphocyte plasmacytoma, ovarian cancer, melanoma, leukemia, colon cancer, breast cancer, lung cancers, and pancreatic cancer.
30 . The method of claim 24 , wherein said pancreatic cancer is adenocarcinoma of the pancreas.